CDKN2A and pancreatic adenocarcinoma: Compared with previous studies and the external TCGA-PAAD analyses, we observed a high frequency of KRAS, TP53, CDKN2A, SMAD4, and losses of 8q (MYC), which is consistent with our report8 (Fig. S1).